Platelet Dynamics During Impella Use: A Time-Series Analysis by Model and Treatment Method

Area of Science:

• Cardiology
• Critical Care Medicine
• Hematology

Background:

• Mechanical circulatory support (MCS) is standard for refractory cardiogenic shock.
• Impella-induced thrombocytopenia is a known complication with limited data.
• Understanding thrombocytopenia progression with different Impella devices and strategies is crucial.

Purpose of the Study:

• To compare thrombocytopenia progression in patients receiving different Impella devices (2.5/CP vs. 5.0/5.5).
• To evaluate thrombocytopenia in Impella-alone versus ECpella (Impella + Venoarterial Extracorporeal Membrane Oxygenation) strategies.
• To identify factors influencing complications and mortality related to Impella use.

Main Methods:

• Retrospective analysis of 121 patients receiving Impella devices between April 2018 and December 2024.
• Patients were categorized by Impella device type (2.5/CP or 5.0/5.5) and support strategy (alone or ECpella).
• Platelet counts, haptoglobin levels, and 1-year survival were analyzed.

Main Results:

• Platelet counts significantly decreased over time in Impella 2.5/CP subgroups, with greater reduction in the ECpella group.
• Significant platelet reduction occurred only in the ECpella subgroup of the Impella 5.0/5.5 group.
• Day 3 post-implantation platelet count was associated with 1-year survival in the Impella 2.5/CP group (HR: 1.174, p=0.014).

Conclusions:

• ECpella strategies may lead to more pronounced thrombocytopenia compared to Impella-alone support.
• Early post-implantation platelet count is a potential predictor of survival in patients supported with Impella 2.5/CP.
• Further validation in larger prospective studies is warranted.